Ask AI
Atopic Dermatitis and IL-4/IL-13 and IL-13 Targeted Therapies
Interactive Case Challenges: Atopic Dermatitis and IL-4/IL-13 and IL-13 Targeted Therapies

Released: April 30, 2025

Activity

Progress
1
Course Completed

Case History and Presentation 
After 6 months of lebrikizumab therapy, Anna shows consistent improvement in her symptoms, and you emphasize to her the importance of transitioning from short-term gains to sustained control. To build on her progress, the following steps are integrated into her care plan: patient education, lifestyle integration, psychosocial support, and periodic monitoring.  

Anna receives detailed guidance on recognizing early signs of flares and how to respond promptly using her approved treatment tool kit. Specific strategies, such as avoiding known triggers (allergens, stressors), are discussed, along with maintaining a structured skin care routine. Anna’s quality of life is assessed using tools like the Dermatology Life Quality Index, and she is referred to support groups or counseling to address any residual emotional distress caused by her chronic condition. You schedule monthly follow-ups to monitor treatment adherence, assess symptom control, and evaluate for any adverse effects of therapy. 

Through these measures, Anna begins to feel empowered in managing her condition and is optimistic about achieving long-term stability. Her AD remains well controlled after 6 months, and she asks you what her long-term expectations are with lebrikizumab.  

What advice would you provide Anna regarding long-term therapy?